Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS

NCT03187288 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Relapsed Cancer
Refractory Cancer

Interventions

DRUG: CFI-400945 Fumarate

Sponsor

University Health Network, Toronto